Neutral on the upgrade: low-accuracy firm, strong consensus already priced in, and negative institutional divergence. With earnings in two days, position defensively—avoid new longs ahead of print.
Price Chart
Executive Summary
BNP Paribas upgraded the stock from Neutral to Outperform with a new $300 price target, implying 13.9% upside from the current $263.40. The move marks a rare double upgrade and comes just two days before the company reports earnings on April 29, 2026. Consensus remains bullish: 67.6% Buy/Strong Buy (37 of 40 analysts), with a mean PT of $296.46. However, BNP Paribas has a weak track record—33% accuracy (1 of 3 calls correct), well below the 70%+ average of top-tier firms. EPS estimates are stable with slight downward revisions over 30 days, while institutional activity shows divergence: Renaissance Technologies fully exited, but Two Sigma increased position by 47.3%. Insider selling totaled $6.5M in early April. Short ratio remains elevated at 58.9%, suggesting ongoing bearish sentiment. Despite the proximity to earnings, the upgrade diverges from recent consensus inertia, though from a low-accuracy firm.
Impact Score
Consensus & Targets
Of 40 analysts, 37 (92.5%) rate Buy or Strong Buy, 15 (37.5%) Hold, and 2 (5%) Sell. No Strong Sell ratings. Buy-side dominance has held steady for six months. BNP Paribas’ new Outperform rating aligns with the bullish consensus but adds no contrarian signal.
Consensus price target mean: $296.46, median: $300, high: $350 (Wedbush), low: $205. Current price: $263.40. Implied upside to mean: +12.5%. BNP Paribas’ $300 PT matches the median, sits 1.2% above the mean, and is 13.9% above current price—modestly aggressive but within the core of the distribution.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-17 | BNP Paribas | upgrade | Outperform | $300.00 |
| 2026-04-14 | B of A Securities | maintain | Buy | $325.00 |
| 2026-03-31 | Wedbush | reiterate | Outperform | $350.00 |
| 2026-03-27 | Wedbush | reiterate | Outperform | $350.00 |
| 2026-03-23 | Morgan Stanley | reiterate | Overweight | $315.00 |
| 2026-03-23 | B of A Securities | maintain | Buy | $320.00 |
| 2026-03-05 | Wedbush | reiterate | Outperform | $350.00 |
| 2026-03-05 | Rosenblatt | maintain | Neutral | $268.00 |
| 2026-03-03 | Barclays | maintain | Underweight | $248.00 |
| 2026-02-17 | Wedbush | reiterate | Outperform | $350.00 |
Over the past 30 days, there has been 1 upgrade (BNP Paribas) and 0 downgrades. EPS revisions show minor downward pressure: 3 down vs 2 up over 30 days for current-year estimates. The +1y EPS forecast has declined slightly from $9.34 to $9.33, indicating softening growth expectations despite strong price momentum.
Firm Track Record — BNP Paribas
BNP Paribas accuracy: 33% on 3 calls | avg return: 2.9%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Oppenheimer | 100% | 4/4 | 3.8% | top tier |
| MoffettNathanson | 100% | 3/3 | -2.2% | top tier |
| Maxim Group | 100% | 4/4 | 14.2% | top tier |
| Tigress Financial | 100% | 4/4 | 10.7% | top tier |
| Melius Research | 100% | 5/5 | 14% | top tier |
| UBS | 83% | 5/6 | 9.5% | top tier |
| Jefferies | 82% | 9/11 | 3.5% | top tier |
| Rosenblatt | 80% | 12/15 | 8.5% | top tier |
| Wedbush | 76% | 19/25 | 10.2% | top tier |
| Bernstein | 75% | 3/4 | 8.8% | top tier |
BNP Paribas has a 33% accuracy rate (1 correct out of 3 scored calls), with an average return of +2.9% on rated stocks. This is materially below top-tier firms like Maxim Group (100%, +14.2%) and Melius Research (100%, +14.0%). Among 15 firms covering the stock, BNP Paribas ranks in the bottom quartile for predictive accuracy.
Earnings Estimates
Next earnings: Apr 29, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $1.94 | $1.56 — $2.16 | $109.3B | ↑1 ↓0 |
| +1y | $9.33 | $8.36 — $10.38 | $497.5B | ↑1 ↓0 |
| +1q | $1.73 | $1.59 — $1.89 | $102.2B | ↑1 ↓0 |
| 0y | $8.51 | $7.96 — $8.97 | $465.5B | ↑2 ↓0 |
Cross-Platform Signals
Contradictory signals: insiders sold $6.5M in early April (Cook, O’Brien). Congressional trades show 4 small sells vs 1 small buy. Institutionally, Renaissance Technologies fully exited ($0 position), while Two Sigma added 47.3%. Short interest remains extreme at 58.9% short ratio. The analyst upgrade diverges from insider and institutional skepticism, particularly from quant funds.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 5w ago | Court Ruling | $332.27 $336.64 | ▲ +1.32% | ▼ −0.55% | $343.46 (+3.37%) |
Sep 10, 2026 5w ago | Court Ruling | $326.57 $340.42 | ▲ +4.24% | ▲ +2.12% | $343.46 (+5.17%) |
Sep 9, 2026 5w ago | Court Ruling | $315.34 $336.67 | ▲ +6.76% | ▲ +4.82% | $343.46 (+8.92%) |
Sep 8, 2026 5w ago | Court Ruling | $316.22 $333.63 | ▲ +5.51% | ▲ +3.79% | $343.46 (+8.61%) |
Sep 3, 2026 6w ago | Court Ruling | $328.21 $333.69 | ▼ −1.67% | ▼ −2.86% | $343.46 (−4.65%) |
Sep 1, 2026 6w ago | 8-K/A | $325.13 $333.09 | ▲ +2.45% | ▲ +2.34% | $343.46 (+5.64%) |
Aug 31, 2026 7w ago | Court Ruling | $316.85 $329.53 | ▲ +4.00% | ▲ +4.37% | $343.46 (+8.40%) |
Aug 27, 2026 7w ago | Court Ruling | $314.58 $341.07 | ▼ −8.42% | ▼ −8.39% | $343.46 (−9.18%) |
Aug 27, 2026 7w ago | Court Ruling | $314.58 $341.07 | ▲ +8.42% | ▲ +8.39% | $343.46 (+9.18%) |
Aug 26, 2026 7w ago | Court Ruling | $313.45 $335.92 | ▲ +7.17% | ▲ +7.03% | $343.46 (+9.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access